Spondyloarthritis & psoriatic arthritis
Persistence of Biologics in the Treatment of Psoriatic Arthritis: Data From a Large Hospital‐Based Longitudinal Cohort
Authors' conclusion
Persistence in taking biologics depends on whether the biologic was used as first or second treatment. Depression and anxiety, higher tender joint count, and older age lead to drug discontinuation.
Study context
- Population
- Patients diagnosed with PsA enrolled in the Toronto cohort who initiated biologic therapy between January 1, 2000, and July 7, 2020
- Participants
- 571 patients
- Exposure
- Biologic therapies and predictors of discontinuation
- Outcome
- Drug persistence (time to discontinuation of first and second biologic treatment)
Methodological detailssingle-centre (Toronto cohort), Cox regression, semiparametric failure time model with gamma frailty
- Single-centre (Toronto cohort)
- Cox regression
- Semiparametric failure time model with gamma frailty
Main finding
As reported in the abstract
Biologic persistence · 3 years
- Highest 3-year persistence probability with certolizumab as first biologic; IL-17 inhibitors lowest
- As second medication, certolizumab had the lowest drug survival even when accounting for selection bias
Observational data: associations, not effects.
Further findings
Predictors of all-cause discontinuation
| RR | P value | |
|---|---|---|
| Depression and/or anxiety | 1.68 | P = 0.01 |
| Higher education | 0.65 | P = 0.03 |
Predictors of discontinuation due to side effects
| RR | P value | |
|---|---|---|
| Older age at start of first treatment | 1.03 | P = 0.01 |
| ObesityProtective role | 0.56 | P = 0.05 |
| Outcome | RR | P value |
|---|---|---|
| Predictors of all-cause discontinuation over multiple courses of biologics | 1.02 | P = 0.01 |
Original publication
Persistence of Biologics in the Treatment of Psoriatic Arthritis: Data From a Large Hospital‐Based Longitudinal Cohort. Arthritis Care Res (Hoboken). Published 12 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →